Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech has initiated registration-enabling studies for their immunotherapy candidate pelareorep, with a focus on HR+/HER2- metastatic breast cancer and pancreatic cancer, buoyed by promising clinical data and FDA engagement. The firm’s financial health appears robust, with a cash reserve of $29.6 million ensuring operations are funded into 2025, as they anticipate key overall survival data from their BRACELET-1 study in the latter half of 2024.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
